| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Myc-Max protein-protein interaction. NY2267 interferes with the formation of the Myc-Max heterodimer, a critical step in c-Myc-dependent transcriptional activation and oncogenesis. By disrupting this interaction, the compound inhibits Myc- and Jun-induced transcriptional activation.
|
|---|---|
| ln Vitro |
NY2267 strongly prevents the oncogenic transformation caused by Myc [1].
In vitro, NY2267 acts as a Myc-Max interaction interferent with an IC50 of 36.5 μM. It inhibits Myc- and Jun-induced transcriptional activation and strongly prevents the oncogenic transformation caused by Myc. |
| ln Vivo |
In vivo activity data for NY2267 are limited in the available literature. Based on its potent in vitro disruption of Myc-Max interaction and inhibition of Myc-induced oncogenic transformation, the compound is expected to exhibit antitumor efficacy in appropriate in vivo models. Further studies are needed to evaluate its pharmacokinetic properties and therapeutic potential in animal models of Myc-driven cancers.
|
| Enzyme Assay |
Myc-Max interaction inhibition is assessed using cell-free protein-protein interaction assays such as fluorescence polarization (FP) or AlphaScreen technology. Recombinant Myc and Max proteins are incubated with varying concentrations of NY2267, and the IC50 value (36.5 μM) is determined by measuring the reduction in signal upon disruption of the protein-protein interaction.
|
| Cell Assay |
Myc-driven cancer cell lines are cultured and treated with NY2267 at varying concentrations for 48-72 hours. Cell viability and proliferation are assessed by CellTiter-Glo or MTT assays. Myc- and Jun-induced transcriptional activation is measured using luciferase reporter assays. Inhibition of oncogenic transformation is evaluated in soft agar colony formation assays.
|
| Animal Protocol |
Specific in vivo protocols for NY2267 are not yet established in the available literature. Standard approaches for evaluating Myc inhibitors would involve xenograft models using Myc-driven human cancer cell lines in immunodeficient mice. The compound would be administered at doses determined from pharmacokinetic studies. Tumor growth inhibition and Myc target gene expression would be assessed.
|
| ADME/Pharmacokinetics |
NY2267 has molecular formula C38H43N3O6 and molecular weight 637.76. It is soluble in DMSO (250 mg/mL, 392.00 mM). The compound is soluble in 10% DMSO + 90% Corn Oil for in vivo formulation (≥2.08 mg/mL, 3.26 mM). Detailed pharmacokinetic parameters such as half-life, Cmax, and oral bioavailability require further characterization.
|
| Toxicity/Toxicokinetics |
No comprehensive toxicity data are currently available for NY2267. As a research-grade Myc-Max interaction inhibitor, its safety profile has not been extensively characterized. Standard preclinical toxicology studies would be necessary to evaluate its safety margin for potential therapeutic applications. The compound is for research use only and is not intended for human or veterinary use.
|
| References | |
| Additional Infomation |
NY2267 is a research-grade small-molecule compound targeting the Myc-Max protein-protein interaction. It is a synthetic compound with CAS number 886053-73-2 and purity ≥98%. The compound is supplied as an off-white to light yellow ointment and should be stored at -20°C. It has not entered clinical trials or received FDA approval. References include publications on Myc inhibition and oncogenic transformation.
|
| Molecular Formula |
C38H43N3O6
|
|---|---|
| Molecular Weight |
637.764530420303
|
| Exact Mass |
637.315
|
| CAS # |
886053-73-2
|
| PubChem CID |
12000419
|
| Appearance |
Off-white to light yellow ointment
|
| LogP |
7.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
47
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)COC1=CC2=C(C=C1)C=C(C=C2)C(C(=O)NC3CCCCC3)N(CC4=CC=C(C=C4)OC)C(=O)C5=CC=CC=N5
|
| InChi Key |
RVGDACCXDZIPOB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C38H43N3O6/c1-38(2,3)47-34(42)25-46-32-20-17-27-22-29(16-15-28(27)23-32)35(36(43)40-30-10-6-5-7-11-30)41(37(44)33-12-8-9-21-39-33)24-26-13-18-31(45-4)19-14-26/h8-9,12-23,30,35H,5-7,10-11,24-25H2,1-4H3,(H,40,43)
|
| Chemical Name |
tert-butyl 2-[6-[2-(cyclohexylamino)-1-[(4-methoxyphenyl)methyl-(pyridine-2-carbonyl)amino]-2-oxoethyl]naphthalen-2-yl]oxyacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (392.00 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5680 mL | 7.8399 mL | 15.6799 mL | |
| 5 mM | 0.3136 mL | 1.5680 mL | 3.1360 mL | |
| 10 mM | 0.1568 mL | 0.7840 mL | 1.5680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
